Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability

Immunology

Volumn 137, Issue 3, 2012, Pages 249-258

  Hock, Barry D ^a   Taylor, Karen G ^a   Cross, Nicholas B ^a   Kettle, Anthony J ^a   Hampton, Mark B ^b   Mckenzie, Judith L ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Arginase; Granulocyte; Immune suppression; Myeloid derived suppressor cells; Polymorphonuclear

Indexed keywords

ARGININE; CATALASE; ENZYME INHIBITOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; MYELOPEROXIDASE; N HYDROXY NOR ARGININE; NITRIC OXIDE SYNTHASE; NITRITE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL DEATH; CELL INTERACTION; CELL STIMULATION; CELL VIABILITY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; HUMANS; LYMPHOCYTE ACTIVATION; NEUTROPHILS; T-LYMPHOCYTES;

EID: 84866857517     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12004     Document Type: Article

References (36)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74.
2. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61:255-63.
3. Muller I, Munder M, Kropf P, Hansch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol 2009; 30:522-30.
4. El-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987; 139:2406-13.
5. Zoschke DC, Messner RP. Suppression of human lymphocyte mitogenesis mediated by phagocyte-released reactive oxygen species: comparative activities in normals and in chronic granulomatous disease. Clin Immunol Immunopathol 1984; 32:29-40.
6. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61:4756-60.
7. Cemerski S, Cantagrel A, Van Meerwijk JP, Romagnoli P. Reactive oxygen species differentially affect T cell receptor-signaling pathways. J Biol Chem 2002; 277:19585-93.
8. Thewissen M, Damoiseaux J, van de Gaar J, Tervaert JW. Neutrophils and T cells: bidirectional effects and functional interferences. Mol Immunol 2011; 48:2094-101.
9. + granulocytes which inhibit T cell function. J Immunol Methods 2009; 341:68-75.
10. low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol 2011; 33:121-9.
11. Rotondo R, Bertolotto M, Barisione G et al. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol 2011; 89:721-7.
12. Munder M, Schneider H, Luckner C et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006; 108:1627-34.
13. Hock BD, Mackenzie KA, Cross NB, Taylor KG, Currie MJ, Robinson BA, Simcock JW, McKenzie JL. Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. Nephrol Dial Transplant 2012; 27:402-10.
14. Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-Demasters BK, Waziri A. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res 2011; 17:6992-7002.
15. Pillay J, Kamp VM, van Hoffen E et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2011; 122:1-10.
16. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69:1553-60.
17. Bronte V, Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 2005; 5:641-54.
18. Solito S, Falisi E, Diaz-Montero CM et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011; 118:2254-65.
19. Brandau S, Trellakis S, Bruderek K et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011; 89:311-7.
20. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57.
21. Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8.
22. Turner NC, Wood LJ, Foster M, Gueremy T. Effects of PAF, FMLP and opsonized zymosan on the release of ECP, elastase and superoxide from human granulocytes. Eur Respir J 1994; 7:934-40.
23. Rafiq K, Charitidou L, Bullens DM, Kasran A, Lorre K, Ceuppens J, van Gool SW. Regulation of the IL-10 production by human T cells. Scand J Immunol 2001; 53:139-47.
24. McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-γ and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-γ production. J Immunol 2002; 169:2736-46.
25. Kettle AJ, Gedye CA, Hampton MB, Winterbourn CC. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J 1995; 308(Pt 2):559-63.
26. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33:153-65.
27. Bonnevier JL, Yarke CA, Mueller DL. Sustained B7/CD28 interactions and resultant phosphatidylinositol 3-kinase activity maintain G1->S phase transitions at an optimal rate. Eur J Immunol 2006; 36:1583-97.
28. Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2000; 164:144-51.
29. Shi M, Lin TH, Appell KC, Berg LJ. Cell cycle progression following naive T cell activation is independent of Jak3/common γ-chain cytokine signals. J Immunol 2009; 183:4493-501.
30. + T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J Immunol 2004; 172:6136-43.
31. Nagaraj S, Youn JI, Weber H et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010; 16:1812-23.
32. + T cells to hydrogen peroxide-induced apoptosis. Genes Immun 2007; 8:560-9.
33. 2 pool generated by human neutrophils. J Biol Chem 1984; 259:399-405.
34. Boucher JL, Genet A, Vadon S, Delaforge M, Mansuy D. Formation of nitrogen oxides and citrulline upon oxidation of N-ω-hydroxy-l-arginine by hemeproteins. Biochem Biophys Res Commun 1992; 184:1158-64.
35. Beranova P, Chalupsky K, Kleschyov AL et al. N-ω-hydroxy-l-arginine homologues and hydroxylamine as nitric oxide-dependent vasorelaxant agents. Eur J Pharmacol 2005; 516:260-7.
36. Andonegui G, Trevani AS, Gamberale R, Carreras MC, Poderoso JJ, Giordano M, Geffner JR. Effect of nitric oxide donors on oxygen-dependent cytotoxic responses mediated by neutrophils. J Immunol 1999; 162:2922-30.